Australian biotech firm Noxopharm (ASX:NOX) has received a significant vote of confidence in its Sofra technology platform, with positive results emerging from a collaboration with leading Chinese biopharmaceutical company BioRay Pharmaceutical.
Under a 2024 material transfer agreement, BioRay tested Noxopharm's oligonucleotide-based assets as part of its ongoing research into autoimmune disease treatments, particularly in the development of antibody-drug conjugates.
The results confirmed two key outcomes: conjugation of Noxopharm's oligo to BioRay's antibody, and a marked enhancement in anti-inflammatory activity, validated by a key biological marker.
This external data serves as independent validation of the Sofra platform’s robustness and therapeutic potential.
BioRay, a major player in China's pharmaceutical sector with over 1,800 employees across sites in Taizhou, Hangzhou, Shanghai, and San Diego, praised the collaboration.
"We are very impressed with the efficacy of the asset supplied to us," said Dr. Gang Chen, Head of R&D at BioRay. "These findings confirm the cutting-edge value of the Sofra platform and the promise of our joint efforts."
Noxopharm CEO Dr. Gisela Mautner welcomed the results, noting they represent just the beginning of multiple MTAs with global partners.
"These findings validate our data and demonstrate the versatility of our Sofra technology," she said.
BioRay will continue testing Noxopharm’s assets in the coming months.
At the time of reporting, Noxopharm's share price was $0.067.